or Try an Advanced Search...

    Technical Analysis for GALT - Galectin Therapeutics Inc.

    Grade Last Price % Change Price Change
    C 2.72 0.00% 0.00
    GALT closed unchanged on Friday, May 31, 2024, on 43 percent of normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
    2 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Up Down Down
    Historical GALT trend table...
    Date Alert Name Type % Chg
    Doji - Bullish? Reversal 0.00%
    Oversold Stochastic Weakness 0.00%
    Outside Day Range Expansion 0.00%
    Down 3 Days in a Row Weakness 0.00%
    Lower Bollinger Band Touch Weakness 0.00%
    Oversold Stochastic Weakness 0.00%
    NR7 Range Contraction -2.51%
    Narrow Range Bar Range Contraction -2.51%
    Stochastic Reached Oversold Weakness -2.51%
    Inside Day Range Contraction -2.51%
    Older End-of-Day Signals for GALT ...

       Recent Intraday Alerts

    Alert Time
    Possible NR7 1 day ago
    Up 3% 1 day ago
    Up 2% 1 day ago
    Fell Below Previous Day's Low 1 day ago
    Lower Bollinger Band Support 1 day ago
    View Earlier Intraday Alerts

    Free Daily (Stock) Chart Reading

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Analyze My Stocks!
    Configure default chart indicators
    GALT Chart by TradingView
    Basic chart:

    Profile

    Galectin Therapeutics Inc., a development stage company, engages in the development of therapies for cancer and fibrotic disease. Its lead product candidates include GR-MD-02, a complex polysaccharide polymer for the treatment of liver fibrosis and fatty liver disease for which the company intends to initiate a Phase I clinical trial in patients with non-alcoholic steatohepatitis; and GM-CT-01, a linear polysaccharide polymer comprising mannose and galactose that is in a Phase I/II clinical trial in Europe as a combination therapy with a tumor vaccine in patients with advanced melanoma. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.
    Classification
    Sector: Healthcare
    Industry: Drug Manufacturers - Specialty & Generic
    Keywords: Cancer Alcohol Tumor Melanoma Hepatitis Steatohepatitis Non Alcoholic Fatty Liver Disease Liver Disease Therapies For Cancer Fibrotic Disease Lectins Liver Fibrosis Galectin Lactose Combination Therapy Fatty Liver Fatty Liver Disease Galectin 3 Galecto Biotech

    Is GALT a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 1 bullish, 2 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    May 15 Galectin Therapeutics GAAP EPS of -$0.19
    May 15 Galectin Therapeutics Reports Financial Results for the Quarter Ended March 31, 2024 and Provides Business Update
    May 13 Galectin Therapeutics to Participate in the H.C. Wainwright BioConnect Conference
    Apr 23 Galectin Therapeutics And 2 Other Penny Stocks Insiders Are Buying
    Apr 9 Galectin Therapeutics Reports the Positive Outcome of the Fifth Data and Safety Monitoring Board Meeting for NAVIGATE Phase 2b/3 Study of Belapectin in Patients with Cirrhotic Portal Hypertension Caused by Metabolic Dysfunction-Associated SteatoHepatitis
    Mar 29 Galectin Therapeutics Inc (GALT) Reports 2023 Financial Results and Business Developments
    Mar 29 Galectin Therapeutics GAAP EPS of -$0.74
    Mar 29 Galectin Therapeutics Reports 2023 Financial Results and Provides Business Update
    Mar 21 Galectin: Q4 2024 NASH Cirrhosis Data Readout Is A Major Inflection Point
    Mar 12 Galectin Therapeutics Expands Clinical Team with the Appointment of Khurram Jamil, M.D. as Vice President, Clinical Development
    See more GALT news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 4.2684
    52 Week Low 1.28
    Average Volume 214,407
    200-Day Moving Average 2.19
    50-Day Moving Average 3.17
    20-Day Moving Average 3.08
    10-Day Moving Average 2.99
    Average True Range 0.23
    RSI (14) 36.71
    ADX 29.35
    +DI 9.01
    -DI 22.17
    Chandelier Exit (Long, 3 ATRs) 2.93
    Chandelier Exit (Short, 3 ATRs) 3.39
    Upper Bollinger Bands 3.50
    Lower Bollinger Band 2.67
    Percent B (%b) 0.07
    BandWidth 27.14
    MACD Line -0.11
    MACD Signal Line -0.05
    MACD Histogram -0.0582
    Fundamentals Value
    Market Cap 168.23 Million
    Num Shares 61.8 Million
    EPS -0.76
    Price-to-Earnings (P/E) Ratio -3.58
    Price-to-Sales 0.00
    Price-to-Book 207.70
    PEG Ratio 0.00
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 2.90
    Resistance 3 (R3) 2.91 2.87 2.87
    Resistance 2 (R2) 2.87 2.82 2.86 2.86
    Resistance 1 (R1) 2.79 2.79 2.78 2.78 2.85
    Pivot Point 2.75 2.75 2.74 2.74 2.75
    Support 1 (S1) 2.67 2.70 2.66 2.66 2.59
    Support 2 (S2) 2.63 2.67 2.62 2.58
    Support 3 (S3) 2.55 2.63 2.57
    Support 4 (S4) 2.54